Comparative Pharmacology
Head-to-head clinical analysis: ERTAPENEM SODIUM versus VABOMERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERTAPENEM SODIUM versus VABOMERE.
ERTAPENEM SODIUM vs VABOMERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. It is a carbapenem antibiotic with broad-spectrum activity against Gram-positive and Gram-negative aerobes and anaerobes.
Vabomere is a combination of meropenem, a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and vaborbactam, a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase (KPC).
1 g IV or IM once daily.
Vabomere (meropenem and vaborbactam) 4 g (meropenem 2 g and vaborbactam 2 g) intravenously every 8 hours infused over 3 hours.
None Documented
None Documented
Terminal half-life: ~4 hours (range 3.5-5.3) in young adults; prolonged in renal impairment (e.g., ~7.5 hours in moderate impairment, ~13 hours in end-stage renal disease)
The terminal elimination half-life is approximately 1 hour for meropenem and 2 hours for vaborbactam in patients with normal renal function. This short half-life supports three-times-daily dosing in patients with creatinine clearance ≥50 mL/min.
Renal: ~80% unchanged in urine; fecal: ~10% as metabolites; biliary: minimal (<1%)
Vabomere (meropenem and vaborbactam) is primarily excreted renally. Approximately 40-50% of meropenem and 75-95% of vaborbactam are excreted unchanged in urine. Biliary/fecal excretion is minimal (<2% for both).
Category A/B
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic